Department of Urology, Ludwig-Maximilian University of Munich, Munich, Germany.
Department of Urology, Ludwig-Maximilian University of Munich, Munich, Germany.
Eur Urol Focus. 2018 Jan;4(1):40-42. doi: 10.1016/j.euf.2018.04.009. Epub 2018 Apr 26.
There is growing interest in minimally invasive (MI) treatment options for male lower urinary tract symptoms (LUTS). Among these options, the temporary implantable nitinol device (TIND; Medi-Tate, Or Akiva, Israel) is a novel instrument used to alleviate symptoms by creating incisions in the prostate via mechanical stress.
To review recent data for TIND as an MI procedure to improve LUTS.
Medline, PubMed, the Cochrane Database, and Embase were screened for clinical trials, randomized controlled trials, and review articles on the use of TIND in patients with male LUTS.
There are currently two studies available, one being a follow-up of the first pilot study. Both 12-mo and 36-mo results suggest at least medium-term effects of TIND in terms of symptom improvement (International Prostate Symptom Score, IPSS) and maximum urinary flow (Q). IPSS was improved by 41% after 12mo (p<0.001) and worsened only insignificantly after 36mo compared to baseline values. Q increased by 4.4ml/s after 12mo (p<0.001) and did not decrease significantly after 36mo. Postoperative complications were mild and included urinary tract infection and urinary retention.
Preliminary data suggest that TIND is a safe and effective MI technique for patients with male LUTS. Symptom relief and increase in urinary flow after 36mo are promising. However, long-term results are needed.
Various treatment options for male patients suffering from urinary voiding symptoms are emerging. TIND, a temporary implantable nitinol device, appears to be a safe option that improves symptoms without affecting sexuality.
微创（MI）治疗男性下尿路症状（LUTS）的选择越来越受到关注。在这些选择中，临时可植入镍钛诺装置（TIND；Medi-Tate，Or Akiva，以色列）是一种新颖的仪器，通过机械应力在前列腺上创建切口来缓解症状。
回顾 TIND 作为 MI 治疗方法改善 LUTS 的最新数据。
通过 Medline、PubMed、Cochrane 数据库和 Embase 筛选了关于 TIND 用于男性 LUTS 患者的临床试验、随机对照试验和综述文章。
目前有两项研究可用，其中一项是第一项试点研究的随访。12 个月和 36 个月的结果均表明 TIND 在症状改善（国际前列腺症状评分，IPSS）和最大尿流率（Q）方面具有至少中期效果。12 个月后 IPSS 改善了 41%（p<0.001），与基线值相比，36 个月后仅略有恶化。12 个月后 Q 增加了 4.4ml/s（p<0.001），36 个月后没有明显下降。术后并发症轻微，包括尿路感染和尿潴留。
初步数据表明，TIND 是治疗男性 LUTS 患者的一种安全有效的 MI 技术。36 个月后症状缓解和尿流增加是有希望的，但需要长期结果。
各种治疗男性患者排尿症状的选择正在出现。TIND，一种临时可植入镍钛诺装置，似乎是一种安全的选择，可改善症状而不影响性功能。
